3 unknown, 1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Diffuse Large B-cell-lymphoma: new trials by email Literature Review of Diffuse Large B-cell-lymphoma trials Research Report on Diffuse Large B-cell-lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma C402-CD19-CAR - Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Recruiting | Shanghai Exuma Biotechnology Ltd. | 18 | 2025-03-25 | 2026-09-11 |
| CD30 Imaging in Diffuse Large B-cell Lymphoma Brentuximab vedotin - Diffuse Large B-cell-lymphoma | Phase 3 | Unknown | University Medical Center Groningen | 20 | 2024-01-01 | 2024-01-02 |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Venetoclax, Rituximab, Ifosfamide - Diffuse Large B-cell-lymphoma | Phase 1 / Phase 2 | Active not recruiting | Molly Gallogly | 65 | 2017-06-26 | 2022-11-16 |
| Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma FDG PET/TC and FDG PET/MRI - Diffuse Large B-cell-lymphoma, Classical Hodgkin Lymphoma | Unknown | Marco Picardi | 120 | 2017-01-24 | 2020-06-12 | |
| High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®), Arm B (TEPADINA®-CARMUBRIS®-Busilvex®) - Diffuse Large B-cell-lymphoma | Phase 3 | Unknown | University Hospital Freiburg | 250 | 2014-07-01 | 2015-08-25 |
Dendritic Cell Sarcoma, Interdigitating (5) · Lymphoma, B-Cell (1) · Pyloric Stenosis, Hypertrophic (1)
Hemic and Lymphatic Diseases (5) · Histiocytic Disorders, Malignant (5) · Histiocytosis (5) · Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Pyloric Stenosis (1)
Brentuximab Vedotin (1) · Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Rituximab (1) · venetoclax (1)
Marco Picardi (1) · Molly Gallogly (1) · Shanghai Exuma Biotechnology Ltd. (1) · University Hospital Freiburg (1) · University Medical Center Groningen (1)
China (1) · Germany (1) · Italy (1) · United States (1)
Andrea Soricelli, Prof (1) · Fabrizio Pane, Prof (1) · Gerald Illerhaus, PhD (1) · Liang Huang, MD (1) · Marcel Nijland, MD (1) · Marco Picardi, Prof (1) · Molly Gallogly, MD PhD (1)
PMID 16864853, PMID 18166803, PMID 18413641, PMID 21745167, PMID 22473593, PMID 27098429, PMID 28153605, PMID 28478586, PMID 31744509, PMID 35398840, PMID 42486133